Esmolol Infusion Rate for Atrial Fibrillation

Clinical Guidelines and Recommendations

The European Society of Cardiology recommends esmolol as a reasonable option for acute rate control in AF patients with hemodynamic instability or severely depressed left ventricular ejection fraction (Class IIb, Level B recommendation) 1

The European Society of Cardiology advises against administering esmolol in patients with signs of heart failure, low output state, or decompensated heart failure 1
Esmolol is contraindicated in patients with second or third-degree heart block without a pacemaker, as recommended by the European Society of Cardiology 1
The European Society of Cardiology also recommends avoiding esmolol in patients with active asthma or reactive airway disease 1
Patients with cardiogenic shock or high risk factors (age >70, systolic BP <120 mmHg, heart rate >110 or <60 bpm) should not receive esmolol, according to the American College of Cardiology 2
Esmolol is contraindicated in pre-excited atrial fibrillation (Wolff-Parkinson-White syndrome) as it may paradoxically accelerate ventricular response, as noted by the American Heart Association 3

Continuous ECG monitoring is required during esmolol infusion, as recommended by the American College of Cardiology 2
Blood pressure and heart rate should be monitored closely, with auscultation for new pulmonary rales (heart failure) and bronchospasm, as advised by the American College of Cardiology 2

The American College of Cardiology warns against administering the full 15 mg as a single rapid bolus, as this significantly increases hypotension and bradycardia risk 2
Esmolol should not be used in decompensated heart failure, and treatment should be delayed until clinical stabilization, as recommended by the European Society of Cardiology 1
The American Heart Association advises against using esmolol in pre-excited AF, as it may accelerate ventricular response through the accessory pathway 3